Antibiotic treatment of Gram-positive bone and joint infections

被引:197
作者
Darley, ESR [1 ]
MacGowan, AP [1 ]
机构
[1] Southmead Gen Hosp, Bristol Ctr Antimicrobial Res & Evaluat, Bristol BS10 5NB, Avon, England
关键词
staphylococci; streptococci; osteomyelitis; septic arthritis; prosthetic joint infections;
D O I
10.1093/jac/dkh191
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Gram-positive organisms, particularly staphylococci and streptococci, are responsible for the majority of bone and joint infections. Treatment of these infections can be difficult, usually involving a prolonged course of antibiotics, often with surgical intervention. The selection of antibiotics depends on sensitivity profile, patient tolerance and long-term goals, e.g. cure or suppression, but there are few randomized controlled trials in patients comparing efficacy of different antibiotics. Different degrees of bone penetration and clinical outcome for specific antibiotics, e.g. the beta-lactams, clindamycin and quinolones, have been described, although the methodology in these studies is not standardized and findings cannot always be applied directly to patients. The effect of attaining minimum serum bactericidal concentrations in patients has also been studied but this is no longer routinely recommended in clinical practice. Comparative clinical trials are few but have demonstrated efficacy of oral fluoroquinolones in combination with either rifampicin or fusidic acid for selected Gram-positive infections. In the past decade, increasingly resistant organisms, e.g. methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci have been recognized as causes of orthopaedic infection. Individual case reports describe successful treatment using the newer antibiotics, e.g. linezolid and quinupristin/dalfopristin, but results of clinical trials are awaited.
引用
收藏
页码:928 / 935
页数:8
相关论文
共 115 条
[71]  
Nathwani D, 1998, INT J CLIN PRACT, V52, P577
[72]   CONCENTRATION OF CLINDAMYCIN IN HUMAN BONE [J].
NICHOLAS, P ;
MEYERS, BR ;
LEVY, RN ;
HIRSCHMAN, SZ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 8 (02) :220-221
[73]   CHRONIC OSTEOMYELITIS CAUSED BY STAPHYLOCOCCUS-AUREUS - CONTROLLED CLINICAL-TRIAL OF NAFCILLIN THERAPY AND NAFCILLIN-RIFAMPIN THERAPY [J].
NORDEN, CW ;
BRYANT, R ;
PALMER, D ;
MONTGOMERIE, JZ ;
WHEAT, J .
SOUTHERN MEDICAL JOURNAL, 1986, 79 (08) :947-951
[74]   EXPERIMENTAL OSTEOMYELITIS .4. THERAPEUTIC TRIALS WITH RIFAMPIN ALONE AND IN COMBINATION WITH GENTAMICIN, SISOMICIN, AND CEPHALOTHIN [J].
NORDEN, CW .
JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (05) :493-499
[76]   TREATMENT OF EXPERIMENTAL CHRONIC OSTEOMYELITIS DUE TO STAPHYLOCOCCUS-AUREUS WITH VANCOMYCIN AND RIFAMPIN [J].
NORDEN, CW ;
SHAFFER, M .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (02) :352-357
[77]   Streptococcus pneumoniae septic arthritis and osteomyelitis in an HIV-seropositive patient [J].
Oliker, R ;
Cunha, BA .
HEART & LUNG, 1999, 28 (01) :74-76
[78]   Linezolid therapy of Staphylococcus aureus experimental osteomyelitis [J].
Patel, R ;
Piper, KE ;
Rouse, MS ;
Steckelberg, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3438-3440
[79]  
*PHARM UPJ LTD, 2000, LIN SUMM PROD CHAR
[80]  
PLOTT MA, 1970, CLIN PHARMACOL THER, V11, P577